Axsome Therapeutics is pleased to announce a new clinical trial of an investigational oral medication, AXS-12, for the treatment of excessive daytime sleepiness and cataplexy associated with narcolepsy. Participation in this study may last up to nine weeks. All enrolled subjects will receive study-related care at no cost.

You may be eligible if you: *

• Are 18-65 years old
• Have a diagnosis of narcolepsy with cataplexy

*The study doctor will discuss additional requirements.

Study sites are located in the following cities: New York, NY; Cincinnati, OH; Miami, FL; Chevy Chase, MD; Austin, TX; Alameda, CA; Colombia, SC; St. Petersburg, FL

To find out more information about this trial and to see if you qualify, please visitwww.theconcertstudy.com or https://clinicaltrials.gov/show/NCT03881852